Investors sold shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on strength during trading on Friday. $31.45 million flowed into the stock on the tick-up and $57.55 million flowed out of the stock on the tick-down, for a money net flow of $26.10 million out of the stock. Of all companies tracked, Alexion Pharmaceuticals had the 0th highest net out-flow for the day. Alexion Pharmaceuticals traded up $0.54 for the day and closed at $110.87

Several equities research analysts recently issued reports on the stock. TheStreet downgraded shares of Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Friday, November 10th. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price target on the stock in a research note on Tuesday, October 31st. Oppenheimer Holdings, Inc. raised shares of Alexion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $175.00 price target on the stock in a research note on Friday, July 28th. Royal Bank Of Canada assumed coverage on shares of Alexion Pharmaceuticals in a research note on Thursday, September 14th. They set an “outperform” rating and a $161.00 price target on the stock. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $153.00 price target (up previously from $141.00) on shares of Alexion Pharmaceuticals in a research note on Friday, July 28th. Six equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $154.01.

The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.51 and a current ratio of 2.96. The company has a market capitalization of $24,769.47, a P/E ratio of 22.67, a PEG ratio of 1.21 and a beta of 1.22.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.32 by $0.12. The firm had revenue of $859.00 million during the quarter, compared to analyst estimates of $864.34 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. Alexion Pharmaceuticals’s revenue was up 7.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.23 EPS. equities research analysts predict that Alexion Pharmaceuticals, Inc. will post 4.81 EPS for the current fiscal year.

In other Alexion Pharmaceuticals news, Director Ann M. Veneman sold 835 shares of the business’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total transaction of $121,751.35. Following the completion of the transaction, the director now directly owns 5,480 shares of the company’s stock, valued at approximately $799,038.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Julie O’neill sold 4,375 shares of the business’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $145.44, for a total transaction of $636,300.00. Following the transaction, the executive vice president now directly owns 26,092 shares of the company’s stock, valued at $3,794,820.48. The disclosure for this sale can be found here. Insiders have sold a total of 16,490 shares of company stock valued at $2,337,251 over the last three months. 4.35% of the stock is currently owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the business. Fiduciary Trust Co. bought a new stake in shares of Alexion Pharmaceuticals during the 2nd quarter worth about $111,000. Huntington National Bank raised its position in shares of Alexion Pharmaceuticals by 1,084.6% during the 2nd quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock worth $131,000 after buying an additional 987 shares in the last quarter. Valeo Financial Advisors LLC bought a new stake in shares of Alexion Pharmaceuticals during the 3rd quarter worth about $147,000. Penserra Capital Management LLC raised its position in shares of Alexion Pharmaceuticals by 13.0% during the 2nd quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 144 shares in the last quarter. Finally, Dupont Capital Management Corp bought a new stake in shares of Alexion Pharmaceuticals during the 3rd quarter worth about $156,000. Institutional investors own 96.71% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://theolympiareport.com/2017/11/19/investors-sell-alexion-pharmaceuticals-inc-alxn-on-strength-alxn-2.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.